T

TG Therapeutics

D
TGTX
USD
0.92
(3.2975%)
Market Closed
142,776.00
حجم التداول
0.37
الربح لكل سهم
-
العائد الربحي
42.382
P/E
4,462,002,808.34
حجم السوق
اليوم
3.2975%
1 اسبوع
7.157%
1 شهر
32.081%
6 اشهر
68.145%
12 اشهر
166.852%
بداية السنة
68.834%
كل الوقت
0%

Title:
TG Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
هل تحتاج مساعدة او لديك استفسار؟